Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Merck
Fish and Richardson
Queensland Health
Chinese Patent Office
Healthtrust
McKinsey
QuintilesIMS
Mallinckrodt

Generated: December 12, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ANGIOTENSIN II

« Back to Dashboard

Clinical Trials for Angiotensin Ii

Trial ID Title Status Sponsor Phase Summary
NCT00000516 Studies of Left Ventricular Dysfunction (SOLVD) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To determine if enalapril treatment of left ventricular dysfunction (LVD) due to ischemic or hypertensive heart disease led to reduced mortality and morbidity in symptomatic and asymptomatic patients. There were a Prevention Trial, a Treatment Trial, and a registry.
NCT00000522 Treatment of Mild Hypertension Study (TOMHS) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT00000522 Treatment of Mild Hypertension Study (TOMHS) Completed University of Minnesota - Clinical and Translational Science Institute Phase 2 To compare the effects of nonpharmacologic therapy alone with those of one of five active drug regimens combined with non-pharmacologic therapy, for long- term management of patients with mild hypertension.
NCT00000531 Antiarrhythmics Versus Implantable Defibrillators (AVID) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To evaluate if use of an implantable cardiac defibrillator (ICD) results in reduction in total mortality, when compared with conventional pharmacological therapy, in patients resuscitated from sudden cardiac death who are otherwise at very high risk of mortality from arrhythmic causes.
NCT00000542 Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To determine if the combined incidence of nonfatal myocardial infarction and coronary heart disease death differs between diuretic-based and each of three alternative antihypertensive pharmacological treatments. Also, to determine, in a subset of this population, if lowering serum cholesterol with a HMG CoA reductase inhibitor in older adults reduces all-cause mortality compared to a control group receiving usual care. Conducted in conjunction with the Department of Veterans' Affairs.
NCT00000543 Oral Calcium in Pregnant Women With Hypertension Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 2 To determine of providing calcium supplementation to women with pre-existing hypertension reduces the level of blood pressure, requirement for antihypertensive drugs, and incidence of pre-eclampsia.
NCT00000547 Enalapril After Anthracycline Cardiotoxicity Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 To determine if the chronic administration of enalapril, an inhibitor of angiotensin converting enzyme (ACE), reduces progression of cardiac dysfunction in pediatric oncology patients who have received anthracyclines, and who are not currently on digoxin, diuretics, or vasodilators for heart failure.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Angiotensin Ii

Condition Name

Condition Name for Angiotensin Ii
Intervention Trials
Hypertension 208
Heart Failure 43
Diabetic Nephropathy 41
Chronic Kidney Disease 36
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Angiotensin Ii
Intervention Trials
Hypertension 207
Kidney Diseases 144
Diabetes Mellitus 89
Heart Failure 87
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Angiotensin Ii

Trials by Country

Trials by Country for Angiotensin Ii
Location Trials
Italy 143
Canada 134
Germany 112
Mexico 65
United Kingdom 58
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Angiotensin Ii
Location Trials
Texas 75
California 71
New York 69
Florida 63
Ohio 63
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Angiotensin Ii

Clinical Trial Phase

Clinical Trial Phase for Angiotensin Ii
Clinical Trial Phase Trials
Phase 4 292
Phase 3 173
Phase 2/Phase 3 25
[disabled in preview] 224
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Angiotensin Ii
Clinical Trial Phase Trials
Completed 453
Recruiting 144
Unknown status 86
[disabled in preview] 179
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Angiotensin Ii

Sponsor Name

Sponsor Name for Angiotensin Ii
Sponsor Trials
National Heart, Lung, and Blood Institute (NHLBI) 46
Takeda 32
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 23
[disabled in preview] 78
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Angiotensin Ii
Sponsor Trials
Other 1026
Industry 299
NIH 101
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Covington
Cantor Fitzgerald
Mallinckrodt
Express Scripts
Julphar
McKesson
Merck
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.